Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
GlobeNewswire
· Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product..